News | January 26, 2024
Syngene Q3 FY 24 PAT up 4% to Rs 115 Cr
For 9 months period ended December 2023, the company’s PAT up 16% to Rs 330 crores (before exceptional items)
For 9 months period ended December 2023, the company’s PAT up 16% to Rs 330 crores (before exceptional items)
An accomplished R&D leader and champion of the application of AI to drug discovery
The company also plans to boost its India presence by adding 1,500 beds in the next 2-3 years
GC1130A has previously achieved notable milestones by securing both RPDD and ODD from the U.S. FDA in January 2023
The receipt of this permission paves way for the launch of Andexanet alfa powder for solution for infusion 200 mg (Andexxa) in India
Produodopa is the first-and-only subcutaneous 24-hour infusion of levodopa-based therapy for the treatment of severe motor fluctuations
Synthon will be responsible for obtaining US regulatory approval for Palbociclib Tablets
Agreed Price of US$43 per share to deliver 48% premium to unaffected price on May 25, 2023
The PAI was conducted for two drug product applications (ANDAs) filed from this facility
Collaboration streamlines patient access to oncology clinical trials
Subscribe To Our Newsletter & Stay Updated
